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PLINICAL RESEARCH Interventional Cardiology
andomized Double-Blind Comparison of
irolimus-Eluting Stent Versus Bare-Metal
tent Implantation in Diseased Saphenous Vein Grafts
ix-Month Angiographic, Intravascular
ltrasound, and Clinical Follow-Up of the RRISC Trial
aul Vermeersch, MD,* Pierfrancesco Agostoni, MD,* Stefan Verheye, MD, PHD,*
aul Van den Heuvel, MD,* Carl Convens, MD,* Nico Bruining, PHD,† Frank Van den Branden, MD,*
lenn Van Langenhove, MD, PHD*
ntwerp, Belgium; and Rotterdam, the Netherlands
OBJECTIVES We sought to compare, in a randomized fashion, sirolimus-eluting stents (SES) versus
bare-metal stents (BMS) in saphenous vein grafts (SVGs).
BACKGROUND Sirolimus-eluting stents reduce restenosis and repeated revascularization in native coronary
arteries compared with BMS. However, randomized data in SVG are absent.
METHODS Patients with SVG lesions were randomized to SES or BMS. All were scheduled to undergo
6-month coronary angiography. The primary end point was 6-month angiographic in-stent
late lumen loss. Secondary end points included binary angiographic restenosis, neointimal
volume by intravascular ultrasound and major adverse clinical events (death, myocardial
infarction, target lesion, and vessel revascularization).
RESULTS A total of 75 patients with 96 lesions localized in 80 diseased SVGs were included: 38 patients
received 60 SES for 47 lesions, whereas 37 patients received 54 BMS for 49 lesions. In-stent
late loss was significantly reduced in SES (0.38 0.51 mm vs. 0.79 0.66 mm in BMS, p
0.001). Binary in-stent and in-segment restenosis were reduced, 11.3% versus 30.6% (relative
risk [RR] 0.37; 95% confidence interval [CI] 0.15 to 0.97, p  0.024) and 13.6% versus
32.6% (RR 0.42; 95% CI 0.18 to 0.97, p  0.031), respectively. Median neointimal volume
was 1 mm3 (interquartile range 0 to 13) in SES versus 24 (interquartile range 8 to 34) in BMS
(p  0.001). Target lesion and vessel revascularization rates were significantly reduced, 5.3%
versus 21.6% (RR 0.24; 95% CI 0.05 to 1.0, p  0.047) and 5.3% versus 27% (RR 0.19; 95%
CI 0.05 to 0.83, p  0.012), respectively. Death and myocardial infarction rates were not
different.
CONCLUSIONS Sirolimus-eluting stents significantly reduce late loss in SVG as opposed to BMS. This
is associated with a reduction in restenosis rate and repeated target lesion and vessel
revascularization procedures. (The RRISC Study; http://clinicaltrials.gov/ct/show;
NCT00263263). (J Am Coll Cardiol 2006;48:2423–31) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.021of Cardiology Foundation
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Taphenous vein grafts (SVGs) remain the most frequently
sed conduits in coronary artery bypass graft surgery (1).
owever, within a decade after surgery, one-half of the
VGs develop significant atherosclerotic disease, and recur-
ent angina after bypass surgery is a common clinical
roblem (2). Repeated bypass surgery is technically more
hallenging than the first operation, and it is associated with
reater morbidity and mortality; thus, currently percutane-
us coronary intervention (PCI) is the preferred treatment
or SVG lesions (3,4). Specifically, the implantation of
are-metal stents (BMS) is the actual strategy to treat these
atients (5,6). However, the results of BMS in SVGs are
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ntwerp, Belgium; and †Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
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ccepted July 18, 2006.ess favorable than those in native vessels, with restenosis
ates exceeding 30% (5,7).
The introduction of sirolimus-eluting stents (SES) re-
ently has reduced the occurrence of angiographic restenosis
nd repeated revascularization with respect to BMS in
ative coronary artery disease (8,9). Despite the growing
vidence of the benefits of SES in several subsets of lesions
10–14) and patients (15,16), SVGs have always been
xcluded from these randomized trials, and currently avail-
ble registries on SES in SVG offer inconsistent results
17–21). Thus, the aim of our study was to assess whether
he use of SES improves angiographic and clinical outcomes
hen compared with BMS in patients with diseased SVGs.
ETHODS
he RRISC (Reduction of Restenosis In Saphenous vein
rafts with Cypher sirolimus-eluting stent) trial is a ran-
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SES Versus BMS in SVGs December 19, 2006:2423–31omized double-blind nonindustry-sponsored trial per-
ormed in a single center with large experience in the
ercutaneous treatment of SVG disease (22,23). The trial
esign was approved by the ethics committee of AZ
iddelheim Hospital.
atient population. Patients were included if they were 18
o 85 years old, had a history of previous coronary artery
ypass surgery, had stable or unstable angina, and had one
r more “de novo” target lesions (50% diameter stenosis
y visual estimate) localized in one or more diseased SVG
ith a reference vessel diameter (RVD) 2.5 and 4.0
m. Exclusion criteria were myocardial infarction (MI)
ithin the previous 7 days (with creatine kinase-myocardial
and elevation 2 times the upper limit of normal),
ocumented left ventricular ejection fraction 25%, im-
aired renal function (creatinine 3.0 mg/dl), distal graft
nastomotic stenosis, totally occluded SVGs, previous
rachytherapy treatment in the index vessel, or and allergy
o aspirin, clopidogrel, heparin, stainless steel, contrast
gent, or sirolimus. Aorto-ostial location and thrombotic
nd/or calcified lesions were not considered exclusion crite-
ia. All enrolled patients provided written informed consent
efore the index procedure.
rocedural protocol. After percutaneous access was ob-
ained, heparin was administered to maintain an activated
lotting time 250 s. Glycoprotein IIb/IIIa receptor block-
rs were given at operator’s discretion. The use of a distal
rotection device (GuardWire, Medtronic, Minneapolis,
innesota) was strongly recommended. After successful
rossing of the target lesion with the guidewire, patients
ere allocated randomly in a 1:1 ratio to treatment with
ypher SES or BX-Velocity BMS (both from Cordis,
ohnson & Johnson, Warren, New Jersey). In case of
reatment of more than one lesion, the stent type remained
he same. Direct stenting was promoted. In case of dissec-
ion or incomplete lesion coverage, the use of additional
tents of the same type as the assigned stent was mandated.
ngiographic success was defined as implantation of the
tudy device with residual diameter stenosis 30% and
ormal (Thrombolysis In Myocardial Infarction-3) coro-
Abbreviations and Acronyms
BMS  bare-metal stent
CI  confidence interval
IVUS  intravascular ultrasound
MACE  major adverse cardiac event
MI  myocardial infarction
MLD  minimal luminal diameter
PCI  percutaneous coronary intervention
RR  relative risk
RVD  reference vessel diameter
SES  sirolimus-eluting stent
SVG  saphenous vein graft
TLR  target lesion revascularization
TVR  target vessel revascularizationary blood flow. Aspirin (100 to 300 mg/day) was given maily, and clopidogrel (loading dose of 300 mg, 6 to 48 h
efore the procedure and 75 mg/day thereafter) was admin-
stered for 2 months in all patients. Serial blood samples for
reatine kinase, creatine kinase-myocardial band and cardiac
roponin I were routinely obtained before the procedure and
t 8, 16, and 24 h after the intervention.
andomization and blinding process. The randomization
rocess was unblocked and nonstratified. The randomiza-
ion list was generated by a computer. Randomization was
erformed by means of opaque envelopes (concealed until
he operator successfully wired the target vessel) containing
letter (i.e., “A” or “B”). Because the standard package of
he stents is the only visible difference between the two stent
ypes, additional external packages, labeled respectively with
A” or “B” and the specific stent measure, were used. The
ppearance of the 2 stent types, once the standard package
as opened, was the same because the delivery system, the
haft, the stent design, and the measures available were the
ame for both. After randomization, the interventional staff
eft the catheterization laboratory, and an independent nurse
pened the package of the stent selected from randomiza-
ion and left the stent on the catheterization table. Thus, the
perator (and his staff) and the patient were unaware of the
tent type.
linical, angiographic, and intravascular ultrasound
IVUS) follow-up. Patients were evaluated clinically 1 and
months after the procedure. Coronary angiography was
epeated at 6 months (15 days) and IVUS analysis was
ecommended in every SVG treated with a study stent.
ntravascular ultrasound was performed after injection of 0.2
g of nitroglycerin with a 30-MHz ultrasound probe
Ultracross 2.9F, Boston Scientific Corporation, Natick,
assachusetts), connected to the Galaxy ultrasound console
Boston Scientific Corporation), and a motorized pullback
speed: 0.5 mm/s). Angiography was performed earlier if
here were recurrent symptoms, but if restenosis was not
ound during this repeated angiography, a new angiography
as performed at 6 months.
uantitative coronary angiographic analysis. Digital
oronary angiograms were analyzed offline by an expert
perator blinded to the procedure (with an intraobserver
ariability for measurements of 5%; range, 2.4% to 9.2%),
sing a validated automated edge detection system (CAAS
I, PIE Medical, Maastricht, the Netherlands). Matched
iews were selected for angiograms recorded before and
mmediately after the intervention and at 6-month follow-
p. Angiographic measurements were made both in the
tent and in the stented segment (defined as the stent plus
he 5-mm edges proximal and distal to the stent) during
iastole using the contrast-filled guiding catheter for mag-
ification calibration. In case overlapping stents were
laced, a single in-stent value was measured, and the
egment was considered as the entirely stented part plus the
mm proximal to the more proximal stent and the 5 mm
istal to the more distal stent implanted. Lesion RVD,
inimal luminal diameter (MLD), percent diameter steno-
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December 19, 2006:2423–31 SES Versus BMS in SVGsis, and length were obtained at baseline. Reference vessel
iameter, MLD, and diameter stenosis were evaluated at
he end of the procedure and at follow-up for the in-stent,
roximal edge, distal edge, and in-segment sections (24).
cute gain was defined as the difference between the
n-stent MLD at the end of the intervention and the MLD
t baseline. Late lumen loss was calculated as the difference
n MLD between measurements immediately after the
rocedure and at follow-up. Binary angiographic restenosis
as defined as diameter stenosis 50% by quantitative
oronary angiography, at the follow-up angiogram (25).
estenosis patterns were assessed using the Mehran classi-
cation system (26).
VUS analysis. Intravascular ultrasound data were stored
n S-VHS videotape. The videotapes were transformed into
he DICOM medical image standard. Quantitative coro-
ary ultrasound analysis was performed using a validated
oftware (Curad, version 4.32, Wijk bij Duurstede, the
etherlands), allowing semiautomated detection of luminal
nd stent boundaries in reconstructed longitudinal planes
27). To obtain a smooth appearance of the vessel wall
tructures in the longitudinal views, the Intelligate image-
ased gating method was applied (28–30). This validated
echnique retrospectively selects end-diastolic frames, allow-
ng more reliable volumetric measurements. Volumetric
uantitative coronary ultrasound analysis was obtained for
tent and lumen. Neointimal volume was computed as the
ifference between the stent volume and the lumen volume.
nd points and definitions. The primary end point of the
tudy was 6-month in-stent late lumen loss. Secondary
ngiographic end points included in-segment late loss and
n-stent and in-segment binary restenosis rate. Secondary
VUS end point was in-stent neointimal volume. The
econdary clinical end points were in-hospital, 30-day, and
-month major adverse cardiac event (MACE) rates.
ACE included death, all nonfatal major MI (also peripro-
edural), and target vessel revascularization (TVR). Major
eriprocedural MI was defined as an elevation of creatine
inase enzyme-myocardial band activity3 times above the
pper limit of normal (16 U/l in our institution). Non-
eriprocedural MI was defined as a new ischemic event with
reatine kinase-myocardial band2 times the upper limit of
ormal, or the electrocardiographic presence of new patho-
ogical Q waves. We also recorded minor periprocedural
yocardial damage, defined as a elevation of cardiac tropo-
in I 0.4 ng/dl (31) or, if preprocedural cardiac troponin
was already positive (in unstable patients), doubling of its
alue at any of the postprocedural samples, without fulfill-
ent of the criteria for major periprocedural MI. Target
esion revascularization (TLR) was defined as a repeated
evascularization procedure (either PCI or coronary bypass
urgery) due to restenosis in the stented segment. Target
essel revascularization was defined as a new revasculariza-
ion procedure in the target vessel, including also TLR.
arget vessel failure was defined as a composite of TVR,reated vessel-related MI, and cardiac death. Stent throm- losis was defined according to Iakovou et al. (32). All the
linical events were adjudicated by an independent clinical
vents committee unaware of the patients’ treatment
ssignment.
tatistical analysis. Sample size was calculated on the as-
umption that the mean per-lesion in-stent late loss in the
MS group would be 1  0.9 mm. To detect a decrease in
ean late loss in the SES group of 0.6 mm, with an 80% power
nd a 2-tailed type I (alpha) error of 0.05, 35 patients per group
ere required. Considering a 10% rate of patients with 1
esion intervention (22,23) and a 15% rate of dropouts, the
umber of enrolled patients was increased by 8%.
All analyses were conducted according to the intention-
o-treat principle. The quantitative angiographic and IVUS
esults were analyzed on a per-lesion basis, whereas the
linical events were assessed per-patient. Continuous data
re expressed as means  standard deviations or as medians
interquartile range] as appropriate, whereas dichotomous
ata are summarized as frequencies. Student t or Mann-
hitney U test (as appropriate) and chi-square or the
isher exact test (as appropriate) have been used, respec-
ively, for continuous and categorical variables, to analyze
ifferences between the 2 study arms. A linear regression
nalysis with the primary end point (in-stent late loss) as
ependent variable and all the baseline clinical and angio-
raphic characteristics known to influence late loss as
ndependent variables (stent type, maximum balloon diam-
ter, maximum inflation pressure, postdilation performed,
otal stent length per lesion, diabetes, age of coronary artery
ypass grafting, baseline lesion length, baseline RVD) also
as performed to confirm the results of our analysis.
elative risks (RRs) with their 95% confidence intervals
CIs) were computed for dichotomous variables. Computa-
ion of the number-needed-to-treat (with 95% CI), extrap-
lated from the absolute risk difference, was made for
linical variables. A 2-sided p value 0.05 was considered
ignificant for all tests.
ESULTS
tudy population and procedural outcomes. Between
eptember 2003 and November 2004, 75 patients with 96
esions localized in 80 SVGs were enrolled (Fig. 1). Baseline
linical characteristics of the patients, as well as the angio-
raphic and procedural characteristics of the lesions treated,
re shown in Table 1. The 2 groups were well balanced for
ll the variables considered. Of a total of 114 stents
eployed, 54 were BMS and 60 SES. Angiographic success
as achieved in all the lesions treated. The use of glyco-
rotein IIb/IIIa inhibitors was very low (only in 1 SES
atient). Distal protection devices were used in more than
0% of the lesions treated. Only in case of distal position of
he stenosis in the vein graft (not enough space for the
lacement of the device), suboptimal back up of the guiding
atheter, or presumed low risk of embolization (very focal
esions), distal protection was not used.
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SES Versus BMS in SVGs December 19, 2006:2423–31ix-month angiographic and IVUS outcomes. None of
he patients was lost to follow-up. At 6 months, 3 SES
atients did not receive angiographic follow-up. An 83-
ear-old man with diabetes died 5 months after the proce-
ure because of severe progressive cardiac failure. The other
patients refused the control angiography. Both were
ompletely symptom-free and without inducible ischemia at
he 6-month clinical visit. Thus, 6-month angiography was
erformed in 37 (100%) BMS patients and in 35 (92%) SES
atients (p  0.24). An IVUS analysis was performed in 59
atients (81.9% of all the patients receiving angiographic
ollow up). Overall, 39 lesions were analyzed in the BMS
roup, whereas 34 lesions were analyzed in the SES group
p  0.40). Reasons for lack of IVUS follow-up in 13
atients included occlusive or subocclusive in-stent resteno-
is that prevented a safe passage of the IVUS probe or poor
rackability of the IVUS probe in the SVG because of the
ortuosity of vessel itself. Patient demographics were not
ifferent between those patients with versus without IVUS
t follow-up.
Angiographic and IVUS data are presented in Table 2.
he primary end point of the study, lesion-based in-stent
ate loss reduction, was met. Also, the linear regression
nalysis showed that the only adjusted predictor of
n-stent late loss remained the type of stent used (p 
igure 1. Complete flowchart of the patients enrolled in the RRISC (Reduc
rial. BMS  bare-metal stent; MI  myocardial infarction; RVD  refe.001). Accordingly, SES showed a significant reduction on all other secondary angiographic and IVUS end points
n a per-lesion analysis. The RR of in-stent or in-
egment restenosis occurrence after SES versus BMS was
.37 (95% CI 0.15 to 0.97) and 0.42 (95% CI 0.18 to
.97), respectively. Among the 6 in-segment binary
estenoses after SES, 1 occurred in the distal edge,
hereas the others were in-stent. Five of 6 were focal
83.3%), and 1 was diffuse (16.7%). No SES-restenotic
cclusion was detected. Four restenoses (66%) occurred
hen multiple SES were deployed to cover one lesion.
ll the 16 in-segment binary restenoses after BMS were
n-stent, apart from 1 that occurred in the proximal edge.
fter BMS implantation, most restenoses (62.5%) had a
on-focal pattern: 7 diffuse (43.8%), 1 proliferative (6.3%),
nd 2 occlusive (12.5%).
n-hospital, 1-month, and 6-month clinical outcomes.
linical events are presented in Table 3. No deaths or
rgent revascularizations occurred during hospitalization.
he rate of major periprocedural MI was 4%, whereas
inor myocardial damage occurred in 17.3% of the patients,
ithout differences between BMS and SES patients (see
able 3 for details). Between the end of the hospitalization
nd the first month after treatment no further events were
ecorded.
After 35 days, 1 MI occurred in a SES patient because
f Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent)
vessel diameter; SES  sirolimus-eluting stent.f the occlusion of a vein graft other than the one treated
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December 19, 2006:2423–31 SES Versus BMS in SVGsable 1. Baseline Clinical and Procedural Characteristics of Patients and Lesions in the Two Groups
BMS
(Patients  37) (Grafts  41)
(Lesions  49) (Stents  54)
SES
(Patients  38) (Grafts  39)
(Lesions  47) (Stents  60) p Value
ge (yrs) 72  8 73  7 0.36
en 33 (89%) 31 (82%) 0.36
isk factors
Family history 29 (78.4%) 25 (65.8%) 0.23
Hypertension 21 (56.8%) 22 (57.9%) 0.84
Hypercholesterolemia 31 (83.8%) 33 (86.9%) 0.74
Current smoker 4 (10.8%) 2 (5.3%) 0.46
Diabetes mellitus 5 (13.5%) 6 (15.8%) 0.78
Body mass index (kg/m2) 26.4  3.9 26.4  3.1 0.97
istory of heart failure 7 (18.9%) 6 (15.8%) 0.72
revious myocardial infarction 15 (40.5%) 17 (44.7%) 0.71
revious coronary angioplasty 15 (40.5%) 12 (31.6%) 0.42
nstable angina pectoris 19 (51.4%) 23 (60.5%) 0.41
jection fraction (%) 72  12 68  18 0.37
ge of the grafts (yrs) 12.6  5.9 12.4  4.6 0.92
umber of grafts treated per patient 0.20
1 33 (89.2%) 37 (97.4%)
2 4 (10.8%) 1 (2.6%)
egenerated saphenous vein grafts* 17 (41.5%) 19 (48.7%) 0.51
umber of lesions treated per patient 0.55
1 26 (70.3%) 29 (76.3%)
2 10 (27%) 9 (23.7%)
3 1 (2.7%) 0 (—)
ecipient native vessel territory 0.11
Left anterior descending/diagonal 6 (12.2%) 9 (19.2%)
Circumflex/obtuse marginal 26 (53.1%) 15 (31.9%)
Right coronary artery 17 (34.7%) 23 (48.9%)
esion location in the graft 0.73
Aorto-ostial 11 (22.4%) 12 (25.5%)
Proximal 13 (26.5%) 12 (25.5%)
Mid 16 (32.7%) 18 (38.3%)
Distal 9 (18.4%) 5 (10.7%)
ngiographic evidence/suspect of thrombus 12 (24.5%) 17 (36.2%) 0.21
oderately/heavily calcified lesions 9 (18.4%) 8 (17%) 0.86
IMI flow preprocedure 0.19
1 2 (4.1%) 2 (4.3%)
2 2 (4.1%) 7 (14.9%)
3 45 (91.8%) 38 (80.9%)
umber of stents per patient 1.46  0.7 1.58  0.7 0.45
1 24 (64.9%) 20 (52.6%)
2 9 (24.3%) 14 (36.8%)
3 4 (10.8%) 4 (10.6%)
umber of stents per lesion 1.11  0.3 1.28  0.5 0.14
1 44 (89.8%) 36 (76.6%)
2 5 (10.2%) 9 (19.1%)
3 0 (—) 2 (4.3%)
otal stent length per patient (mm) 33.4  18.2 36.9  17.6 0.39
Range 8–79 18–89
otal stent length per lesion (mm) 25.2  11.9 29.9  15.6 0.11
Range 8–66 8–89
se of distal protection device per lesion 41 (83.7%) 37 (78.7%) 0.53
Median [IQR] time of occlusion with distal protection balloon (s) 140 [120–168] 165 [130–260] 0.08
uccessful direct stenting 44 (89.8%) 44 (93.6%) 0.50
ostdilation 7 (14.3%) 14 (29.8%) 0.09
tent length (mm) 22.9  8.0 23.4  7.0 0.28
tent diameter (mm) 3.36  0.26 3.41  0.19 0.72
aximal balloon diameter (mm) 3.44  0.38 3.56  0.37 0.09
aximal inflation pressure (atm) 18.8  2.2 18.7  2.8 0.85
ata are presented as numbers (%) or mean  standard deviation, unless otherwise specified. *Degenerated saphenous vein grafts are defined as grafts with luminal irregularities
nvolving 50% of their total length.
BMS  bare-metal stent; IQR  interquartile range; SES  sirolimus-eluting stent; TIMI  Thrombolysis In Myocardial Infarction.
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SES Versus BMS in SVGs December 19, 2006:2423–31n the index procedure. After 5 months, a patient in the
ES group died, as previously described. The rates of
LR and TVR (all ischemia-driven PCI, namely PCI
erformed because of anginal complains or evidence of
yocardial ischemia at exercise or pharmacological stress
est) were significantly reduced after SES with respect to
MS: 5.3% versus 21.6% (p  0.047) and 5.3% versus
7% (p  0.012), respectively. The RR for TLR was 0.24
95% CI 0.05 to 1.0), whereas for TVR it was 0.19 (95%
Table 2. Quantitative Coronary Angiography a
of Lesions Treated in the Two Groups
Quantitative coronary angiography
Preprocedure
Reference vessel diameter (mm) 3
Minimal luminal diameter (mm) 1
Diameter stenosis (%)
Lesion length (mm) 1
Postprocedure
In-segment
Minimal luminal diameter (mm) 2
Diameter stenosis (%)
Proximal edge
Minimal luminal diameter (mm) 3
Diameter stenosis (%)
In-stent
Minimal luminal diameter (mm) 2
Diameter stenosis (%)
Acute gain (mm) 1
Distal edge
Minimal luminal diameter (mm) 2
Diameter stenosis (%)
Follow-up
In-segment
Minimal luminal diameter (mm) 1
Diameter stenosis (%)
Proximal edge
Minimal luminal diameter (mm) 2
Diameter stenosis (%)
In-stent
Minimal luminal diameter (mm) 1
Diameter stenosis (%)
Distal edge
Minimal luminal diameter (mm) 2
Diameter stenosis (%)
Late loss (mm)
In-segment 0
Proximal edge 0
In-stent 0
Distal edge 0
Binary angiographic restenosis
In-stent
In-segment
Intravascular ultrasound volumetric analysis
Follow-up
Stent length (mm) 21.
Stent volume (mm3) 21
Lumen volume (mm3) 17
Neointimal volume (mm3) 2
Data are presented as numbers (%), mean  standard devia
BMS  bare-metal stent; SES  sirolimus-eluting stentI 0.05 to 0.83). Number-needed-to-treat calculation ghowed that assigning 6 (3 to 175) patients to SES
revents a TLR with respect to BMS. Moreover, 5 (2 to
9) patients should be treated with SES to prevent a
VR. All TVR occurred at 6 months apart from 2 in the
MS group (1 at 2 months and 1 at 4 months);
urthermore, 2 patients who received BMS underwent
LR in 2 lesions each. Indeed, on a per-lesion analysis
he RR of TLR was 0.21 (95% CI 0.05 to 0.90). The
umulative MACE rate was not different between the 2
ntravascular Ultrasound Volumetric Analysis
S SES p Value
49) (n  47)
0.72 3.28  0.57 0.63
0.51 1.05  0.51 0.35
13 68  13 0.33
9 18.6  11 0.27
49) (n  47)
0.54 2.76  0.51 0.15
8 17  6 0.37
0.61 3.29  0.60 0.08
7 6  8 0.48
0.44 2.88  0.42 0.18
11 14  7 0.12
0.58 1.83  0.53 0.06
0.71 2.99  0.68 0.26
10 9  11 0.58
49) (n  44)
0.87 2.33  0.68 0.010
23 28  16 0.008
0.79 3.10  0.68 0.21
12 10  10 0.83
0.89 2.49  0.67 0.002
23 23  18 0.001
0.82 2.79  0.71 0.22
16 13  13 0.99
0.61 0.40  0.51 0.015
0.55 0.17  0.48 0.97
0.66 0.38  0.51 0.001
0.50 0.19  0.51 0.61
.6%) 5 (11.3%) 0.024
.6%) 6 (13.6%) 0.031
39) (n  34)
.1–30.9] 23.4 [18.8–31.6] 0.14
3–282] 214 [174–325] 0.23
5–243] 205 [174–310] 0.023
34] 1 [0–13] 0.001
r median [interquartile range].nd I
BM
(n 
.34 
.14 
66 
6.2 
(n 
.60 
16 
.08 
7 
.77 
12 
.62 
.83 
8 
(n 
.90 
39 
.91 
10 
.97 
38 
.59 
13 
.70 
.17 
.79 
.24 
15 (30
16 (32
(n 
2 [17
1 [14
5 [12
4 [8–
tion, oroups. No stent thrombosis was recorded.
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ecurrent angina after coronary artery bypass surgery is a
ommon clinical problem. Within 10 years after the oper-
tion, half of all SVGs are totally occluded or have severe
therosclerotic disease (2). Although the implantation of
MS is the actual percutaneous strategy to treat patients
ith SVG lesions, the incidence of angiographic restenosis
nd repeated revascularization remains high (5,7,19). Im-
lantation of SES has the potential to become the new
herapeutic approach (19,20), but there has been no pro-
pective comparison of BMS and SES in SVGs.
Our study is the first randomized comparison of SES
ersus BMS in patients with diseased SVGs. Our data show
hat in this challenging setting the use of SES effectively
educes late lumen loss when compared with BMS. Late
umen loss has been extensively used in interventional
ardiology trials as a reliable end point for 2 reasons. First,
ate lumen loss is a surrogate for in-stent neointimal
yperplasia (which is the pathological process that can lead
o in-stent restenosis) (33). Accordingly, our IVUS data
emonstrate that SES efficiently inhibits neointimal hyper-
lasia in SVG: a complete absence of neointimal growth was
vident in 47% of the SES lesions versus only 2.5% of the
MS lesions. Second, recent data have shown that late
umen loss is a robust parameter to compare different types
f stents and to predict binary angiographic and clinical
ifferences (33,34). Although our study was underpowered
o assess clinical end points, the beneficial angiographic and
VUS outcomes translated into a significant advantage in
erms of binary restenosis, TLR and TVR, which suggests a
linical benefit for SES over BMS also in diseased SVGs,
Table 3. In-Hospital, 30-Day, and 6-Month C
In-hospital
Death
Repeat revascularization
Major periprocedural myocardial infarction
Minor periprocedural myocardial damage
Median cardiac troponin I increase (ng/dl) [r
From discharge to 30 days
Death
Repeat revascularization
Myocardial infarction
Between 1 and 6 months
Death
Myocardial infarction
TLR (per patient)
TVR (per patient)
Cumulative 6-month MACE
TVF (per patient)
TLR (per lesion)
TVR (per lesion)
TVF (per lesion)
Data are presented as numbers (%), unless otherwise specifie
BMS  bare-metal stent; MACE  major adverse cardia
sirolimus-eluting stent; TLR  target lesion revascularizatio
myocardial infarction, or TVR); TVR  target vessel revascainly for a reduced revascularization procedure rate. The mnding of relative risk reductions of approximately 60% for
estenosis and of around 80% for repeated revascularization
urther substantiates this benefit, as these values compare
ell with those obtained in trials performed in native
oronary arteries (8–16).
Our trial is the first randomized study to date performed
n de novo SVG lesions to show a significant angiographic
enefit. Neither the pivotal Saphenous Vein De novo trial
or the recent Venestent trial were able to show a significant
eduction in binary angiographic restenosis (which was the
rimary end point of both studies) of BMS versus balloon
ngioplasty (5,6). Furthermore, in these 2 trials, the late
oss of BMS was comparable with that of balloon an-
ioplasty, if not worse. Other devices have been recently
ested in diseased SVG, with disappointing results (35,36).
embrane-covered stents have been proposed as new op-
ion to reduce the restenotic process (35), but results from
everal randomized trials failed to show a significant benefit
ver standard BMS (36–38). In percutaneous SVG treat-
ent, only the WRIST SVG (Washington Radiation for
n-Stent Restenosis Trial for Saphenous Vein Graft) study
howed a significant reduction of all the angiographic and
linical end points adding radiation therapy to conventional
reatment (39). However, this trial assessed only in-stent
estenotic SVG lesions; thus, its results cannot be extrapo-
ated to de novo SVG lesions.
xternal validity. Several issues remain to be evaluated.
irst, the possible risk of late stent thrombosis, which has
een already shown for native coronary arteries (40,41), also
hould be considered in a potentially favorable milieu such
s SVG. Indeed, plaques in SVGs are lipid-rich, soft, and
al Events in the Two Groups
BMS (n  37) SES (n  38) p Value
0 0
0 0
1 (2.7%) 2 (5.3%) 0.99*
4 (10.8%) 9 (23.7%) 0.14
4.71 [0.43–5.33] 2.18 [0.54–9.01] 0.82
0 0
0 0
0 0
0 1 (2.6%) 0.99*
0 1 (2.6%) 0.99*
8 (21.6%) 2 (5.3%) 0.047*
10 (27%) 2 (5.3%) 0.012*
11 (29.7%) 6 (15.8%) 0.15
11 (29.7%) 5 (13.2%) 0.08
10/49 (20.4%) 2/47 (4.3%) 0.017
12/49 (24.5%) 2/47 (4.3%) 0.005
13/49 (26.5%) 5/47 (10.6%) 0.046
sher exact test.
ts (death, any major myocardial infarction, or TVR); SES 
F  target vessel failure (cardiac death, target vessel-related
tion.linic
ange]
d. *Fi
c evenore prone to rupture than plaques in native coronary
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SES Versus BMS in SVGs December 19, 2006:2423–31rteries (42). In addition, the histopathology of SVG after
tent implantation is a mixture of cellular hyperplasia,
rogression of atherosclerosis, local inflammatory reaction
o metallic stent struts, and thrombosis (43,44). Second,
onger-term outcomes also may be compromised by late
ES restenosis, a phenomenon that was recently described
n native coronary arteries (45) and that can be potentially
xacerbated by the specific pathology of SVGs. Finally,
ecause of the exclusion criteria of our trial, our data do not
pply to large SVGs (with RVD 4.0 mm), to in-stent
estenotic lesions, to occluded vein grafts, to lesions local-
zed in the distal vein graft anastomosis, and to patients
reated for acute MI related to a sudden SVG occlusion.
tudy limitations. The main limitations of our study are
nherent to the monocentric design and the small sample
ize, which was underpowered for major clinical end points
nd led to broad confidence intervals for the assessment of
he relative risks and the number needed to treat for
epeated revascularization procedures. Therefore, the possi-
le existence of type I (alpha) or II (beta) error for all the
econdary end points should not be dismissed. In particular,
he rate of periprocedural myocardial damage (as assessed by
roponin elevation) was more than double after SES, despite
his increase was nonsignificant.
In light of the nondefinitive clinical results of this trial,
e welcome future larger trials, with a multicenter design,
o unquestionably show a clinical benefit of SES in SVG
ith respect to BMS. In particular, these trials should
ainly focus on potentially harmful events, such as late
estenosis and stent thrombosis.
onclusions. Our study has shown that, in diseased SVGs,
ES significantly reduce 6-month angiographic late lumen
oss as opposed to BMS. This reduction is associated with a
eduction in binary restenosis rate and repeated target lesion
nd target vessel revascularization procedures.
eprint requests and correspondence: Dr. Paul Vermeersch, Ant-
erp Cardiovascular Institute Middelheim, AZ Middelheim, Lin-
endreef 1, 2020 Antwerp, Belgium. E-mail: paul.vermeersch@
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